What is the sentiment of this tweet? Please choose an answer from {negative/neutral/positive}.

$BIIB - Questions Linger After CTAD For Biogen's Aducanumab, But Trading Opportunities Exist. Follow this and any o… https://t.co/gNTMKMWrzT
neutral